These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 26329535)
1. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse. Norwood CW; Wright ER Res Social Adm Pharm; 2016; 12(3):509-14. PubMed ID: 26329535 [TBL] [Abstract][Full Text] [Related]
2. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment. Norwood CW; Wright ER Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489 [TBL] [Abstract][Full Text] [Related]
3. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495 [TBL] [Abstract][Full Text] [Related]
4. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575 [TBL] [Abstract][Full Text] [Related]
5. Examination of psychosocial predictors of Virginia pharmacists' intention to utilize a prescription drug monitoring program using the theory of planned behavior. Gavaza P; Fleming M; Barner JC Res Social Adm Pharm; 2014; 10(2):448-58. PubMed ID: 23953982 [TBL] [Abstract][Full Text] [Related]
6. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350 [TBL] [Abstract][Full Text] [Related]
7. Educating Pharmacists on a Prescription Drug Monitoring Program. Fleming ML; Phan Y; Ferries EA; Hatfield MD J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949 [TBL] [Abstract][Full Text] [Related]
8. Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers. Wright RE; Reed N; Carnes N; Kooreman HE Pain Physician; 2016 Jan; 19(1):E197-208. PubMed ID: 26752487 [TBL] [Abstract][Full Text] [Related]
9. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522 [TBL] [Abstract][Full Text] [Related]
10. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases. Arnold A; Bentley JP; Patel A; Holmes E J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328 [TBL] [Abstract][Full Text] [Related]
11. Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice. Cochran G; Field C; Lawson K J Pharm Pract; 2015 Aug; 28(4):404-12. PubMed ID: 24532819 [TBL] [Abstract][Full Text] [Related]
12. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse. Fleming ML; Bapat SS; Varisco TJ Res Social Adm Pharm; 2019 Aug; 15(8):992-999. PubMed ID: 30442574 [TBL] [Abstract][Full Text] [Related]
13. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use. Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394 [TBL] [Abstract][Full Text] [Related]
14. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost. Upton C; Gernant SA; Rickles NM J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293 [TBL] [Abstract][Full Text] [Related]
15. Assessment of risk behaviors in patients with opioid prescriptions: A study of indiana's inspect data. Greene MS; Chambers RA; Yiannoutsos CT; Wright ER; Steele GK; Zollinger TW Am J Addict; 2017 Dec; 26(8):822-829. PubMed ID: 29143401 [TBL] [Abstract][Full Text] [Related]
16. Do no harm: the role of community pharmacists in regulating public access to prescription drugs in Saudi Arabia. Bahnassi A Int J Pharm Pract; 2016 Apr; 24(2):142-5. PubMed ID: 26383607 [TBL] [Abstract][Full Text] [Related]
17. Prescription drug monitoring program utilization in Kentucky community pharmacies. Wixson SE; Blumenschein K; Goodin AJ; Talbert J; Freeman PR Pharm Pract (Granada); 2015; 13(2):540. PubMed ID: 26131042 [TBL] [Abstract][Full Text] [Related]
18. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454 [TBL] [Abstract][Full Text] [Related]
19. Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists. Blackmer J; Lindahl E; Strahl A; Schadler A; Freeman PR J Am Pharm Assoc (2003); 2019; 59(3):379-382. PubMed ID: 30786971 [TBL] [Abstract][Full Text] [Related]
20. Disclosure of Use and Abuse of Controlled Substances Among Psychiatric Outpatients. De Marco Centeno P; Baig M; Lee SE; Lane CJ; Lagomasino IT J Psychiatr Pract; 2015 Nov; 21(6):412-8. PubMed ID: 26554323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]